An expert from Rutgers Cancer Institute discusses ongoing research for mosunetuzumab in relapsed/refractory follicular lymphoma, as well as the importance of deploying the agent in the community setting.
Approval Alert | Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma
An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access.
An expert from Rutgers Cancer Institute reviews data that lead to the approval of mosunetuzumab for patients with relapsed/refractory follicular lymphoma.
The FDA’s decision to approve mosunetuzumab marks the first bispecific antibody approved to treat follicular lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
Achieving a “Functional Cure” With Multiple Myeloma Therapy
5